PMC:7324763 / 77047-77682 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1240","span":{"begin":0,"end":5},"obj":"CHEBI:35472;CHEBI:35472"},{"id":"T1241","span":{"begin":84,"end":90},"obj":"UBERON:0002405;GO:0006955"},{"id":"T1242","span":{"begin":91,"end":100},"obj":"GO:0006955"},{"id":"T1243","span":{"begin":124,"end":134},"obj":"GO:0042571"},{"id":"T1244","span":{"begin":141,"end":150},"obj":"CHEBI:5855;CHEBI:5855"},{"id":"T1245","span":{"begin":210,"end":219},"obj":"CHEBI:5855;CHEBI:5855"},{"id":"T1246","span":{"begin":254,"end":264},"obj":"GO:0010467"},{"id":"T1247","span":{"begin":272,"end":276},"obj":"G_3;PG_10;PR:000003622"},{"id":"T1248","span":{"begin":315,"end":325},"obj":"SP_7"},{"id":"T1249","span":{"begin":326,"end":331},"obj":"NCBITaxon:10239;GO:0035376"},{"id":"T1250","span":{"begin":332,"end":337},"obj":"GO:0035376"},{"id":"T1251","span":{"begin":417,"end":425},"obj":"SP_7"},{"id":"T1252","span":{"begin":451,"end":460},"obj":"CHEBI:5855;CHEBI:5855"},{"id":"T1253","span":{"begin":470,"end":476},"obj":"CHEBI:35472;CHEBI:35472"},{"id":"T1254","span":{"begin":545,"end":550},"obj":"PR:000000017"},{"id":"T1255","span":{"begin":555,"end":560},"obj":"PR:000000134;GO:0032640"},{"id":"T1256","span":{"begin":561,"end":571},"obj":"GO:0032640"},{"id":"T1257","span":{"begin":617,"end":625},"obj":"SP_7"},{"id":"T47072","span":{"begin":0,"end":5},"obj":"CHEBI:35472;CHEBI:35472"},{"id":"T70483","span":{"begin":84,"end":90},"obj":"UBERON:0002405;GO:0006955"},{"id":"T5444","span":{"begin":91,"end":100},"obj":"GO:0006955"},{"id":"T46572","span":{"begin":124,"end":134},"obj":"GO:0042571"},{"id":"T16119","span":{"begin":141,"end":150},"obj":"CHEBI:5855;CHEBI:5855"},{"id":"T35977","span":{"begin":210,"end":219},"obj":"CHEBI:5855;CHEBI:5855"},{"id":"T46174","span":{"begin":254,"end":264},"obj":"GO:0010467"},{"id":"T58823","span":{"begin":272,"end":276},"obj":"G_3;PG_10;PR:000003622"},{"id":"T10504","span":{"begin":315,"end":325},"obj":"SP_7"},{"id":"T61782","span":{"begin":326,"end":331},"obj":"NCBITaxon:10239;GO:0035376"},{"id":"T47807","span":{"begin":332,"end":337},"obj":"GO:0035376"},{"id":"T12613","span":{"begin":417,"end":425},"obj":"SP_7"},{"id":"T40182","span":{"begin":451,"end":460},"obj":"CHEBI:5855;CHEBI:5855"},{"id":"T89863","span":{"begin":470,"end":476},"obj":"CHEBI:35472;CHEBI:35472"},{"id":"T60778","span":{"begin":545,"end":550},"obj":"PR:000000017"},{"id":"T93145","span":{"begin":555,"end":560},"obj":"PR:000000134;GO:0032640"},{"id":"T95675","span":{"begin":561,"end":571},"obj":"GO:0032640"},{"id":"T36464","span":{"begin":617,"end":625},"obj":"SP_7"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T875","span":{"begin":537,"end":544},"obj":"Body_part"},{"id":"T876","span":{"begin":540,"end":544},"obj":"Body_part"}],"attributes":[{"id":"A875","pred":"fma_id","subj":"T875","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A876","pred":"fma_id","subj":"T876","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T538","span":{"begin":315,"end":323},"obj":"Disease"},{"id":"T539","span":{"begin":315,"end":319},"obj":"Disease"},{"id":"T540","span":{"begin":417,"end":425},"obj":"Disease"},{"id":"T541","span":{"begin":617,"end":625},"obj":"Disease"}],"attributes":[{"id":"A538","pred":"mondo_id","subj":"T538","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A539","pred":"mondo_id","subj":"T539","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A540","pred":"mondo_id","subj":"T540","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A541","pred":"mondo_id","subj":"T541","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T918","span":{"begin":220,"end":223},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T919","span":{"begin":506,"end":507},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T920","span":{"begin":537,"end":544},"obj":"http://purl.obolibrary.org/obo/CL_0000623"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T72788","span":{"begin":0,"end":5},"obj":"Chemical"},{"id":"T203","span":{"begin":141,"end":150},"obj":"Chemical"},{"id":"T33962","span":{"begin":210,"end":219},"obj":"Chemical"},{"id":"T73535","span":{"begin":451,"end":460},"obj":"Chemical"},{"id":"T209","span":{"begin":470,"end":476},"obj":"Chemical"}],"attributes":[{"id":"A44750","pred":"chebi_id","subj":"T72788","obj":"http://purl.obolibrary.org/obo/CHEBI_35475"},{"id":"A70212","pred":"chebi_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/CHEBI_132922"},{"id":"A53671","pred":"chebi_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/CHEBI_5855"},{"id":"A49516","pred":"chebi_id","subj":"T33962","obj":"http://purl.obolibrary.org/obo/CHEBI_132922"},{"id":"A18566","pred":"chebi_id","subj":"T33962","obj":"http://purl.obolibrary.org/obo/CHEBI_5855"},{"id":"A93547","pred":"chebi_id","subj":"T73535","obj":"http://purl.obolibrary.org/obo/CHEBI_132922"},{"id":"A79410","pred":"chebi_id","subj":"T73535","obj":"http://purl.obolibrary.org/obo/CHEBI_5855"},{"id":"A1039","pred":"chebi_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/CHEBI_35475"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2168","span":{"begin":272,"end":276},"obj":"Gene"},{"id":"2169","span":{"begin":545,"end":550},"obj":"Gene"},{"id":"2170","span":{"begin":555,"end":560},"obj":"Gene"},{"id":"2171","span":{"begin":315,"end":325},"obj":"Species"},{"id":"2172","span":{"begin":626,"end":634},"obj":"Species"},{"id":"2173","span":{"begin":141,"end":150},"obj":"Chemical"},{"id":"2174","span":{"begin":210,"end":219},"obj":"Chemical"},{"id":"2175","span":{"begin":451,"end":460},"obj":"Chemical"},{"id":"2176","span":{"begin":417,"end":425},"obj":"Disease"},{"id":"2177","span":{"begin":617,"end":625},"obj":"Disease"}],"attributes":[{"id":"A2168","pred":"tao:has_database_id","subj":"2168","obj":"Gene:59272"},{"id":"A2169","pred":"tao:has_database_id","subj":"2169","obj":"Gene:3458"},{"id":"A2170","pred":"tao:has_database_id","subj":"2170","obj":"Gene:7124"},{"id":"A2171","pred":"tao:has_database_id","subj":"2171","obj":"Tax:2697049"},{"id":"A2172","pred":"tao:has_database_id","subj":"2172","obj":"Tax:9606"},{"id":"A2173","pred":"tao:has_database_id","subj":"2173","obj":"MESH:D007052"},{"id":"A2174","pred":"tao:has_database_id","subj":"2174","obj":"MESH:D007052"},{"id":"A2175","pred":"tao:has_database_id","subj":"2175","obj":"MESH:D007052"},{"id":"A2176","pred":"tao:has_database_id","subj":"2176","obj":"MESH:C000657245"},{"id":"A2177","pred":"tao:has_database_id","subj":"2177","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T181","span":{"begin":84,"end":100},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}

{"project":"MyTest","denotations":[{"id":"32655581-19345936-34771861","span":{"begin":191,"end":194},"obj":"19345936"},{"id":"32655581-32171062-34771862","span":{"begin":287,"end":290},"obj":"32171062"},{"id":"32655581-17083365-34771863","span":{"begin":573,"end":576},"obj":"17083365"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}

{"project":"TEST0","denotations":[{"id":"32655581-191-198-3171434","span":{"begin":191,"end":194},"obj":"[\"19345936\"]"},{"id":"32655581-90-97-3171435","span":{"begin":287,"end":290},"obj":"[\"32171062\"]"},{"id":"32655581-103-110-3171436","span":{"begin":573,"end":576},"obj":"[\"17083365\"]"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}

{"project":"2_test","denotations":[{"id":"32655581-19345936-34771861","span":{"begin":191,"end":194},"obj":"19345936"},{"id":"32655581-32171062-34771862","span":{"begin":287,"end":290},"obj":"32171062"},{"id":"32655581-17083365-34771863","span":{"begin":573,"end":576},"obj":"17083365"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T466","span":{"begin":0,"end":196},"obj":"Sentence"},{"id":"T467","span":{"begin":197,"end":338},"obj":"Sentence"},{"id":"T468","span":{"begin":339,"end":469},"obj":"Sentence"},{"id":"T469","span":{"begin":470,"end":635},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"NSAID therapy should be used with caution as they have been shown to interfere with immune responses and ability to produce antibodies, with ibuprofen having the greatest suppressive effect (266). Furthermore, ibuprofen has been reported to increase the expression of the ACE2 receptor (267) which could facilitate SARS-CoV-2 viral entry. This finding should be considered for any current (NCT04334629) and potential COVID-19 clinical trial assessing ibuprofen therapy. NSAIDs also have been shown to have a direct suppressive effect on NK cell IFN-γ and TNF-α production (268) which may be beneficial for late stage COVID-19 patients."}